Cabergoline (BioDeep_00000006681)
Secondary id: BioDeep_00001868190
human metabolite blood metabolite Chemicals and Drugs
代谢物信息卡片
1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea
化学式: C26H37N5O2 (451.2947102)
中文名称: 卡麦角林
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C=CCN1CC(C(=O)N(CCCN(C)C)C(O)=NCC)CC2c3cccc4[nH]cc(c34)CC21
InChI: InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)
描述信息
Cabergoline is only found in individuals that have used or taken this drug. It is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors. The dopamine D2 receptor is a 7-transmembrane G-protein coupled receptor associated with Gi proteins. In lactotrophs, stimulation of dopamine D2 causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca2+ from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D2 receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D1, alpha1,- and alpha2- adrenergic, and 5-HT1- and 5-HT2-serotonin receptors.
G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CB - Prolactine inhibitors
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents
N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists
C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist
Cabergoline is an ergot derived-dopamine D2-like receptor agonist that has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively).
同义名列表
25 个代谢物同义名
1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea; N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide; (8beta)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8b)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8Β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; 1-Ethyl-2-(3-dimethylaminopropyl)-3-(6-allylergoline-8-beta-carbonyl)urea diphosphate; (8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; 1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-Allylergoline-8b-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-((6-Allylergolin-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-((6-Allylergolin-8b-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-Ethyl-3-(3-dimethylamionpropyl)-2-(6-allylergoline-8beta-carbonyl)urea; 1-Ethyl-3-(3-dimethylamionpropyl)-2-(6-allylergoline-8b-carbonyl)urea; 1-Ethyl-3-(3-dimethylamionpropyl)-2-(6-allylergoline-8β-carbonyl)urea; Cabergoline diphosphate; Cabergolinum; Cabergoline; Cabergolina; Cabaseril; Galastop; Dostinex; Cabaser; FCE-21336
数据库引用编号
21 个数据库交叉引用编号
- ChEBI: CHEBI:91795
- ChEBI: CHEBI:3286
- KEGG: C08187
- KEGGdrug: D00987
- PubChem: 54746
- PubChem: 2512
- HMDB: HMDB0014393
- Metlin: METLIN1454
- DrugBank: DB00248
- ChEMBL: CHEMBL1898147
- ChEMBL: CHEMBL1201087
- Wikipedia: Cabergoline
- MeSH: Cabergoline
- chemspider: 49452
- CAS: 1426173-20-7
- CAS: 81409-90-7
- PMhub: MS000019760
- PubChem: 10387
- NIKKAJI: J134.029H
- RefMet: Cabergoline
- medchemexpress: HY-15296
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- James D Gilbert, Stephen J Rossiter, Nigel C Bennett, Christopher G Faulkes. The elusive role of prolactin in the sociality of the naked mole-rat.
Hormones and behavior.
2022 07; 143(?):105196. doi:
10.1016/j.yhbeh.2022.105196. [PMID: 35597054] - Anna Rückl, Donald L Thompson, Jean-Michel Hatt. Effect of the Prolactin Inhibitor Cabergoline and the Gonadotropin Releasing-Hormone Agonist Deslorelin in the Suppression of Plasma Prolactin Concentrations and Egg Laying in Quail (Coturnix japonica).
Journal of avian medicine and surgery.
2022 May; 36(1):39-52. doi:
10.1647/20-00075. [PMID: 35526163] - Hongli Li, Fei Wang, Zhenyu Zhou, Xi Jiang, Fei Li, Yaru Feng, Chuhe Liu, Yu Zhang, Shengjie Fan, Xiaojun Wu, Cheng Huang. Atractylon, a novel dopamine 2 receptor agonist, ameliorates Parkinsonian like motor dysfunctions in MPTP-induced mice.
Neurotoxicology.
2022 03; 89(?):121-126. doi:
10.1016/j.neuro.2022.01.010. [PMID: 35104500] - Luiz Henrique Corrêa Portari, Silvia Regina Correa-Silva, Julio Abucham. Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.
Neuroendocrinology.
2022; 112(1):68-73. doi:
10.1159/000514591. [PMID: 33477154] - Robert Krysiak, Karolina Kowalcze, Bogusław Okopień. Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study.
Cardiology.
2022; 147(5-6):497-506. doi:
10.1159/000527333. [PMID: 36195057] - Rosa Pirchio, Chiara Graziadio, Annamaria Colao, Rosario Pivonello, Renata S Auriemma. Metabolic effects of prolactin.
Frontiers in endocrinology.
2022; 13(?):1015520. doi:
10.3389/fendo.2022.1015520. [PMID: 36237192] - Lina You, Haidong Jiang. Cabergoline possesses a beneficial effect on blood-brain barrier (BBB) integrity against lipopolysaccharide (LPS).
Bioengineered.
2021 12; 12(1):8358-8369. doi:
10.1080/21655979.2021.1987066. [PMID: 34592907] - Tse-Yu Chen, Chung-Hsin Lee, Meng-Yin Yang, Chiung-Chyi Shen, Yin-Ping Yang, Yueh Chien, Yu-Fen Huang, Chih-Ming Lai, Wen-Yu Cheng. Treatment of hyperprolactinemia: A single-institute experience.
Journal of the Chinese Medical Association : JCMA.
2021 11; 84(11):1019-1022. doi:
10.1097/jcma.0000000000000584. [PMID: 34261980] - Mohammed Ahmed Fouad Shalaby, Hekma A Abd El Latif, Mohamed El Yamani, May Ahmed Galal, Sherifa Kamal, Ikhlas Sindi, Raneem Masaood. Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes.
BMC pharmacology & toxicology.
2021 10; 22(1):64. doi:
10.1186/s40360-021-00526-6. [PMID: 34702339] - Isabelle Boucoiran, Melissa Roy, Vanessa Poliquin, Chelsea Elwood, Nancy L Sheehan, Rosie Thibaudeau, Ema Ferreira, Julie Autmizguine, Fatima Kakkar, Marc Boucher, Deborah Money, Karen Tulloch. Evaluation of cabergoline for lactation inhibition in women living with HIV.
International journal of STD & AIDS.
2021 06; 32(7):654-661. doi:
10.1177/0956462420984694. [PMID: 33612017] - Anna Sophia Posawetz, Christian Trummer, Marlene Pandis, Felix Aberer, Thomas R Pieber, Barbara Obermayer-Pietsch, Stefan Pilz, Verena Theiler-Schwetz. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study.
BMC endocrine disorders.
2021 Apr; 21(1):81. doi:
10.1186/s12902-021-00733-6. [PMID: 33902531] - Ismet Hortu, Elif Karadadas, Gokay Ozceltik, Erol Tavmergen, Ege Nazan Tavmergen Goker, Gurkan Yigitturk, Oytun Erbas. Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model.
Archives of gynecology and obstetrics.
2021 04; 303(4):1099-1108. doi:
10.1007/s00404-020-05855-1. [PMID: 33140116] - Lukas Andereggen, Janine Frey, Emanuel Christ. Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated.
Endocrine.
2021 04; 72(1):216-222. doi:
10.1007/s12020-020-02557-1. [PMID: 33275185] - Ved Bhushan Arya, Simon J B Aylwin, Tony Hulse, Michal Ajzensztejn, Jennifer Kalitsi, Nicolas Kalogirou, Istvan Bodi, Nick Thomas, Tim Hampton, Ritika R Kapoor, Charles R Buchanan. Prolactinoma in childhood and adolescence-Tumour size at presentation predicts management strategy: Single centre series and a systematic review and meta-analysis.
Clinical endocrinology.
2021 03; 94(3):413-423. doi:
10.1111/cen.14394. [PMID: 33340135] - Mohammadesmaeil Alipour, Maryam Jafarian, Reza Rastgoo, Azarakhsh Mokri, Ali Gorji, Mohammad R Zarrindast, Fahimeh Lorestani, Emran M Razaghi. Cabergoline in Treatment of Methamphetamine-Dependent Patients and Its Effect on Serum Level of Glial Cell-Derived Neurotrophic Factor: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
European addiction research.
2021; 27(6):457-468. doi:
10.1159/000515398. [PMID: 33857946] - Rosa Pirchio, Renata S Auriemma, Domenico Solari, Mauro Arnesi, Claudia Pivonello, Mariarosaria Negri, Cristina de Angelis, Luigi M Cavallo, Paolo Cappabianca, Annamaria Colao, Rosario Pivonello. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.
Frontiers in endocrinology.
2021; 12(?):769744. doi:
10.3389/fendo.2021.769744. [PMID: 34917030] - Mohammad M Ghahremanpour, Julian Tirado-Rives, Maya Deshmukh, Joseph A Ippolito, Chun-Hui Zhang, Israel Cabeza de Vaca, Maria-Elena Liosi, Karen S Anderson, William L Jorgensen. Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
ACS medicinal chemistry letters.
2020 Dec; 11(12):2526-2533. doi:
10.1021/acsmedchemlett.0c00521. [PMID: 33324471] - G Caja, A Elhadi, X Such, A A K Salama. Suppression of prolactin and reduction of milk secretion by effect of cabergoline in lactating dairy ewes.
Journal of dairy science.
2020 Dec; 103(12):12033-12044. doi:
10.3168/jds.2019-18087. [PMID: 33041043] - Manjeetkaur Sehemby, Anurag Ranjan Lila, Vijaya Sarathi, Ravikumar Shah, Shilpa Sankhe, Sanjeet Kumar Jaiswal, Swati Ramteke-Jadhav, Virendra Patil, Nalini Shah, Tushar Bandgar. Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline.
The Journal of clinical endocrinology and metabolism.
2020 12; 105(12):. doi:
10.1210/clinem/dgaa650. [PMID: 32942295] - Haipeng Huang, Yasushi Takai, Kouki Samejima, Tatsuya Narita, Shunichiro Ichinose, Yukiko Itaya, Yoshihisa Ono, Shigetaka Matsunaga, Masahiro Saitoh, Kazunori Baba, Naoki Hayashi, Hiroyuki Seki. Late-onset ovarian hyperstimulation syndrome developing during ovarian stimulation in an ectopic pregnancy: a case report.
Journal of medical case reports.
2020 Jul; 14(1):110. doi:
10.1186/s13256-020-02439-0. [PMID: 32684165] - Maria Fleseriu, Olaf M Dekkers, Niki Karavitaki. Endocrinology in the time of COVID-19: Management of pituitary tumours.
European journal of endocrinology.
2020 Jul; 183(1):G17-G23. doi:
10.1530/eje-20-0473. [PMID: 32369770] - Campbell Le Heron, Nils Kolling, Olivia Plant, Annika Kienast, Rebecca Janska, Yuen-Siang Ang, Sean Fallon, Masud Husain, Matthew A J Apps. Dopamine Modulates Dynamic Decision-Making during Foraging.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
2020 07; 40(27):5273-5282. doi:
10.1523/jneurosci.2586-19.2020. [PMID: 32457071] - Elif İlknur Ekici, Mehmet Güney, Mustafa Nazıroğlu. Protective effect of cabergoline on mitochondrial oxidative stress-induced apoptosis is mediated by modulations of TRPM2 in neutrophils of patients with endometriosis.
Journal of bioenergetics and biomembranes.
2020 06; 52(3):131-142. doi:
10.1007/s10863-020-09830-y. [PMID: 32227254] - Hiroyo Hashimoto, Hideaki Miyachi, Koki Kataoka, Yugo Maru, Yaei Togawa, Hiroyuki Matsue. Case of fertility treatment-induced Stevens-Johnson syndrome with a severe ocular complication.
The Journal of dermatology.
2019 Nov; 46(11):1042-1045. doi:
10.1111/1346-8138.15072. [PMID: 31489686] - Robert Krysiak, Bogusław Okopień. Sexual Functioning in Hyperprolactinemic Patients Treated With Cabergoline or Bromocriptine.
American journal of therapeutics.
2019 Jul; 26(4):e433-e440. doi:
10.1097/mjt.0000000000000777. [PMID: 29746287] - Aura D Herrera-Martínez, Rosanna van den Dungen, Fadime Dogan-Oruc, Peter M van Koetsveld, Michael D Culler, Wouter W de Herder, Raúl M Luque, Richard A Feelders, Leo J Hofland. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
Endocrine-related cancer.
2019 06; 26(6):585-599. doi:
10.1530/erc-19-0086. [PMID: 30939452] - Richard A Feelders, John Newell-Price, Rosario Pivonello, Lynnette K Nieman, Leo J Hofland, Andre Lacroix. Advances in the medical treatment of Cushing's syndrome.
The lancet. Diabetes & endocrinology.
2019 04; 7(4):300-312. doi:
10.1016/s2213-8587(18)30155-4. [PMID: 30033041] - Motofumi Koguchi, Yukiko Nakahara, Ryo Ebashi, Atsushi Ogata, Shoko Shimokawa, Jun Masuoka, Tatsuya Abe. Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report.
Journal of medical case reports.
2019 Jan; 13(1):18. doi:
10.1186/s13256-018-1939-x. [PMID: 30660191] - Sheyda Jouhari, Afsaneh Mohammadzadeh, Haleh Soltanghoraee, Zohreh Mohammadi, Shaheen Khazali, Ebrahim Mirzadegan, Niknam Lakpour, Farnaz Fatemi, Simin Zafardoust, Arash Mohazzab, Mohammad Mehdi Naderi. Effects of silymarin, cabergoline and letrozole on rat model of endometriosis.
Taiwanese journal of obstetrics & gynecology.
2018 Dec; 57(6):830-835. doi:
10.1016/j.tjog.2018.10.011. [PMID: 30545536] - Hui Yang, Xia Li, Feng Xue, Qunli Xia, Xin Zhao, Dixin Wang, Lihong Chen, Hua Cao, Han Xu, Xiaoyan Shen, Weiru Yuan, Xiaoqing Zhao, Ruofei Shi, Jie Zheng. Local production of prolactin in lesions may play a pathogenic role in psoriatic patients and imiquimod-induced psoriasis-like mouse model.
Experimental dermatology.
2018 11; 27(11):1245-1253. doi:
10.1111/exd.13772. [PMID: 30120801] - Saba Khanam, Falaq Naz, Fahad Ali, Rahul Smita Jyoti, Ambreen Fatima, Wasi Khan, Braj Raj Singh, A H Naqvi, Yasir Hasan Siddique. Effect of cabergoline alginate nanocomposite on the transgenic Drosophila melanogaster model of Parkinson's disease.
Toxicology mechanisms and methods.
2018 Nov; 28(9):699-708. doi:
10.1080/15376516.2018.1502386. [PMID: 30019977] - Hai Yan Huang, Shao Jian Lin, Wei Guo Zhao, Zhe Bao Wu. Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review.
Metabolic brain disease.
2018 06; 33(3):969-976. doi:
10.1007/s11011-018-0217-3. [PMID: 29546691] - Mehrnaz Imani, Mohammad Ebrahim Khamseh, Poopak Asadi, Mohammad Ghorbani, Hamideh Akbari, Fariba Alaei-Shahmiri, Maryam Honardoost, Mahmoud Reza Kaynama, Mojtaba Malek. COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
2018 Jun; 24(6):542-547. doi:
10.4158/ep-2017-0195. [PMID: 29949429] - Yuen-Siang Ang, Sanjay Manohar, Olivia Plant, Annika Kienast, Campbell Le Heron, Kinan Muhammed, Michele Hu, Masud Husain. Dopamine Modulates Option Generation for Behavior.
Current biology : CB.
2018 05; 28(10):1561-1569.e3. doi:
10.1016/j.cub.2018.03.069. [PMID: 29731299] - Itziar Montalvo, Marta Llorens, Laia Caparrós, Montserrat Pamias, Jordi Torralbas, Olga Giménez-Palop, Assumpta Caixàs, Diego J Palao, Javier Labad. Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma.
International clinical psychopharmacology.
2018 03; 33(2):98-102. doi:
10.1097/yic.0000000000000199. [PMID: 29035904] - Chimeddulam Erdenebaatar, Munekage Yamaguchi, Fumitaka Saito, Mahina Monsur, Ritsuo Honda, Hironori Tashiro, Takashi Ohba, Hidetaka Katabuchi. Administration of Cabergoline Contributes to Preserving Fertility in Young Hyperprolactinemic Patients With Endometrial Cancer Treated With Medroxyprogesterone Acetate.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
2018 03; 28(3):539-544. doi:
10.1097/igc.0000000000001196. [PMID: 29369118] - Behnaz Bameri, Fatemeh Shaki, Nematollah Ahangar, Ramin Ataee, Mahedeh Samadi, Hamidreza Mohammadi. Evidence for the Involvement of the Dopaminergic System in Seizure and Oxidative Damage Induced by Tramadol.
International journal of toxicology.
2018 Mar; 37(2):164-170. doi:
10.1177/1091581817753607. [PMID: 29554822] - Cristina Cosio, Elena Sartori, Marcello Garatti, Lorenzo Luccardini, G C M Grinwis, Hans S Kooistra, Federico Fracassi. Prolactinoma in a Dog.
Veterinary pathology.
2017 11; 54(6):972-976. doi:
10.1177/0300985817726118. [PMID: 28812531] - Miriam A Bredella, Melanie Schorr, Laura E Dichtel, Anu V Gerweck, Brian J Young, Whitney W Woodmansee, Brooke Swearingen, Karen K Miller. Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly.
The Journal of clinical endocrinology and metabolism.
2017 11; 102(11):4218-4225. doi:
10.1210/jc.2017-01210. [PMID: 28945897] - Ricardo Costa, C A Santa-Maria, D M Scholtens, S Jain, L Flaum, W J Gradishar, C V Clevenger, V G Kaklamani. A pilot study of cabergoline for the treatment of metastatic breast cancer.
Breast cancer research and treatment.
2017 Oct; 165(3):585-592. doi:
10.1007/s10549-017-4370-x. [PMID: 28674764] - Shalini Kunasegaran, Michael S Croxson, Ian Holdaway, Rinki Murphy. An unusual case of Cushing's syndrome due to bihormonal ACTH-prolactin secreting pituitary macroadenoma with rapid response to cabergoline.
BMJ case reports.
2017 Aug; 2017(?):. doi:
10.1136/bcr-2017-219921. [PMID: 28784879] - Margarida Teixeira, Pedro Souteiro, Davide Carvalho. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.
Pituitary.
2017 Aug; 20(4):464-470. doi:
10.1007/s11102-017-0806-x. [PMID: 28523537] - F Hasanpour, M Taei, S H Banitaba, M Heidari. Template synthesis of maghemite nanoparticle in carboxymethyl cellulose and its application for electrochemical cabergoline sensing.
Materials science & engineering. C, Materials for biological applications.
2017 Jul; 76(?):88-93. doi:
10.1016/j.msec.2017.02.128. [PMID: 28482603] - Robert Krysiak, Witold Szkróbka, Bogusław Okopień. Alternative Treatment Strategies in Women Poorly Tolerating Moderate Doses of Bromocriptine.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
2017 Jun; 125(6):360-364. doi:
10.1055/s-0042-123041. [PMID: 28073129] - A Ferriere, C Cortet, P Chanson, B Delemer, P Caron, O Chabre, Y Reznik, J Bertherat, V Rohmer, C Briet, I Raingeard, F Castinetti, A Beckers, L Vroonen, D Maiter, F L Cephise-Velayoudom, M L Nunes, M Haissaguerre, A Tabarin. Cabergoline for Cushing's disease: a large retrospective multicenter study.
European journal of endocrinology.
2017 Mar; 176(3):305-314. doi:
10.1530/eje-16-0662. [PMID: 28007845] - Asghar Mogheiseh, Mohammad Javad Mosavi Ghiri, Esmaeil Bandarian. The Clinical Follow-Up of Estradiol Benzoate Priming During Induction of Estrus With Cabergoline in Dogs.
Topics in companion animal medicine.
2017 Mar; 32(1):16-19. doi:
10.1053/j.tcam.2017.07.001. [PMID: 28750784] - Shinya Watanabe, Hiroyoshi Akutsu, Shingo Takano, Tetsuya Yamamoto, Eiichi Ishikawa, Hiroaki Suzuki, Akira Matsumura. Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal.
Clinical endocrinology.
2017 Feb; 86(2):207-213. doi:
10.1111/cen.13240. [PMID: 27651307] - Verena Schwetz, Rosaria Librizzi, Christian Trummer, Georg Theiler, Claudia Stiegler, Thomas R Pieber, Barbara Obermayer-Pietsch, Stefan Pilz. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.
Metabolic brain disease.
2017 02; 32(1):155-161. doi:
10.1007/s11011-016-9882-2. [PMID: 27525431] - Selma Mourad, Julie Brown, Cindy Farquhar. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.
The Cochrane database of systematic reviews.
2017 01; 1(?):CD012103. doi:
10.1002/14651858.cd012103.pub2. [PMID: 28111738] - Pedro Iglesias, Carles Villabona, Juan José Díez. [Serum concentrations of glucose, cholesterol and triglycerides in men with prolactinoma treated with cabergoline].
Medicina clinica.
2016 Nov; 147(10):466-467. doi:
10.1016/j.medcli.2016.05.025. [PMID: 27452305] - Ilyas M Eli, Amol Raheja, Heather J Corn, Debra L Simmons, Cheryl Ann Palmer, William T Couldwell. Sellar Wegener Granulomatosis Masquerading as Cabergoline-Resistant Prolactinoma.
World neurosurgery.
2016 Nov; 95(?):622.e1-622.e5. doi:
10.1016/j.wneu.2016.07.108. [PMID: 27521731] - Adele Bahar, Zahra Kashi, Ezzatossadat Daneshpour, Ozra Akha, Shahram Ala. Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial.
Medicine.
2016 Oct; 95(40):e4818. doi:
10.1097/md.0000000000004818. [PMID: 27749534] - Laura D Ratner, Guillermina Stevens, Maria Marta Bonaventura, Victoria A Lux-Lantos, Matti Poutanen, Ricardo S Calandra, Ilpo T Huhtaniemi, Susana B Rulli. Hyperprolactinemia induced by hCG leads to metabolic disturbances in female mice.
The Journal of endocrinology.
2016 07; 230(1):157-69. doi:
10.1530/joe-15-0528. [PMID: 27154336] - M Boutinaud, N Isaka, V Lollivier, F Dessauge, E Gandemer, P Lamberton, A I De Prado Taranilla, A Deflandre, L M Sordillo. Cabergoline inhibits prolactin secretion and accelerates involution in dairy cows after dry-off.
Journal of dairy science.
2016 Jul; 99(7):5707-5718. doi:
10.3168/jds.2015-10782. [PMID: 27179868] - Nur Şahin, Nesin Apaydın, Emrah Töz, Oya Nermin Sivrikoz, Mine Genç, Gülüzar Arzu Turan, Hakan Cengiz, Fatma Eskicioğlu. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
Archives of gynecology and obstetrics.
2016 May; 293(5):1101-6. doi:
10.1007/s00404-015-3987-4. [PMID: 26690356] - Pia Burman, Britt Edén-Engström, Bertil Ekman, F Anders Karlsson, Erik Schwarcz, Jeanette Wahlberg. Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.
European journal of endocrinology.
2016 Jan; 174(1):17-24. doi:
10.1530/eje-15-0807. [PMID: 26582653] - Annelien De Pue, Bart Lutin, Koen Paemeleire. Chronic cluster headache and the pituitary gland.
The journal of headache and pain.
2016; 17(?):23. doi:
10.1186/s10194-016-0614-0. [PMID: 26969187] - Iván E Laboy-Ortiz, Sharon Velez-Maymí, José Hernán Martínez, Rafael Trinidad, Michelle Mangual, Alfredo Sanchez, Madeline Gutierrez, Paola Mansilla, Carmen Rivera, Coromoto Palermo, María de Lourdes Miranda, Ricardo Brau. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
Boletin de la Asociacion Medica de Puerto Rico.
2016; 108(1):31-36. doi:
NULL. [PMID: 29193928] - Eider Pascual-Corrales, Alejandra Tomás Velázquez, José Luis Zubieta, Javier Salvador, Juan Carlos Galofré. Cabergoline for Cushing's disease: A case report.
Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.
2015 Dec; 62(10):516-8. doi:
10.1016/j.endonu.2015.07.002. [PMID: 26307390] - Emmanuelle Kuhn, Luigi Maione, Amir Bouchachi, Myriam Rozière, Sylvie Salenave, Sylvie Brailly-Tabard, Jacques Young, Peter Kamenicky, Patrick Assayag, Philippe Chanson. Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study.
European journal of endocrinology.
2015 Nov; 173(5):693-702. doi:
10.1530/eje-15-0500. [PMID: 26429918] - Muzaffer Ilhan, Ozlem Timirci Kahraman, Saime Turan, Seda Turgut, Ozcan Karaman, Umit Zeybek, Samir Shukurov, Ilhan Yaylim, Ertugrul Tasan. Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?.
Annales d'endocrinologie.
2015 Oct; 76(5):614-9. doi:
10.1016/j.ando.2015.08.005. [PMID: 26514951] - A Bach, A De-Prado, A Aris. Short communication: The effects of cabergoline administration at dry-off of lactating cows on udder engorgement, milk leakages, and lying behavior.
Journal of dairy science.
2015 Oct; 98(10):7097-101. doi:
10.3168/jds.2015-9751. [PMID: 26277312] - R Krysiak, J Okrzesik, B Okopien. Different Effects of Metformin on the Hypothalamic-Pituitary-Thyroid Axis in Bromocriptine- and Cabergoline-treated Patients with Hashimoto's Thyroiditis and Glucose Metabolism Abnormalities.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
2015 Oct; 123(9):561-6. doi:
10.1055/s-0035-1564073. [PMID: 26372847] - F S Cunha, S Domenice, V L Câmara, M H P Sircili, L J G Gooren, B B Mendonça, E M F Costa. Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy.
Andrologia.
2015 Aug; 47(6):680-4. doi:
10.1111/and.12317. [PMID: 25059808] - Mussa H Almalki, Badurudeen Buhary, Saad Alzahrani, Fahad Alshahrani, Safia Alsherbeni, Ghada Alhowsawi, Naji Aljohani. Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases.
Pituitary.
2015 Jun; 18(3):405-9. doi:
10.1007/s11102-014-0588-3. [PMID: 25062894] - A Arduc, F Gokay, S Isik, U Ozuguz, G Akbaba, Y Tutuncu, D Berker, F K Kucukler, Y Aydin, S Guler. Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.
Journal of endocrinological investigation.
2015 Apr; 38(4):447-53. doi:
10.1007/s40618-014-0212-4. [PMID: 25421155] - Robert Krysiak, Bogusław Okopien. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Basic & clinical pharmacology & toxicology.
2015 Mar; 116(3):251-6. doi:
10.1111/bcpt.12307. [PMID: 25123447] - Hadar Amir, Dan Yaniv, Joseph Hasson, Ami Amit, David Gordon, Foad Azem. Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial.
The Journal of reproductive medicine.
2015 Jan; 60(1-2):48-54. doi:
NULL. [PMID: 25745751] - Elzbieta Andrysiak-Mamos, Agnieszka Kaźmierczyk-Puchalska, Ewa Zochowska, Elzbieta Sowińska-Przepiera, Leszek Sagan, Ireneusz Kojder, Anhelli Syrenicz. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
Pomeranian journal of life sciences.
2015; 61(3):263-9. doi:
NULL. [PMID: 27344867] - Renata S Auriemma, Mariano Galdiero, Pasquale Vitale, Luciana Granieri, Fabio Lo Calzo, Ciro Salzano, Lucia Ferreri, Claudia Pivonello, Federica Cariati, Giorgio Coppola, Cristina de Angelis, Annamaria Colao, Rosario Pivonello. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas.
Neuroendocrinology.
2015; 101(1):66-81. doi:
10.1159/000371851. [PMID: 25592453] - M Lombardi, I Lupi, M Cosottini, G Rossi, L Manetti, V Raffaelli, C Sardella, E Martino, F Bogazzi. Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
2014 Dec; 46(13):939-42. doi:
10.1055/s-0034-1389925. [PMID: 25230324] - Ratchaneewan Kwancharoen, Renata Simona Auriemma, Gayane Yenokyan, Gary S Wand, Annamaria Colao, Roberto Salvatori. Second attempt to withdraw cabergoline in prolactinomas: a pilot study.
Pituitary.
2014 Oct; 17(5):451-6. doi:
10.1007/s11102-013-0525-x. [PMID: 24078319] - Kari A Morfeld, Ray L Ball, Janine L Brown. Recurrence of hyperprolactinemia and continuation of ovarian acyclicity in captive African elephants (Loxodonta africana) treated with cabergoline.
Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians.
2014 Sep; 45(3):569-76. doi:
10.1638/2013-0254r.1. [PMID: 25314824] - Sarwar Malik, Syed Zubair Hussain, Rabia Basit, Najia Idress, Aysha Habib, Muhammad Zamant, Najmul Islam. Demographic characteristics, presentations and treatment outcome of patients with prolactinoma.
Journal of Ayub Medical College, Abbottabad : JAMC.
2014 Jul; 26(3):269-74. doi:
NULL. [PMID: 25671924] - R van der Pas, J H M van Esch, C de Bruin, A H J Danser, A M Pereira, P M Zelissen, R Netea-Maier, D M Sprij-Mooij, I M van den Berg-Garrelds, R H N van Schaik, S W J Lamberts, A H van den Meiracker, L J Hofland, R A Feelders. Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy.
European journal of endocrinology.
2014 Feb; 170(2):181-91. doi:
10.1530/eje-13-0477. [PMID: 24165019] - Marina Boscolo, Danielle Baleriaux, Nathalie Bakoto, Bernard Corvilain, France Devuyst. Acute aseptic meningitis as the initial presentation of a macroprolactinoma.
BMC research notes.
2014 Jan; 7(?):9. doi:
10.1186/1756-0500-7-9. [PMID: 24398140] - Alessandro Ciresi, Marco Calogero Amato, Valentina Guarnotta, Flavia Lo Castro, Carla Giordano. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
Clinical endocrinology.
2013 Dec; 79(6):845-52. doi:
10.1111/cen.12204. [PMID: 23506485] - R van der Pas, C de Bruin, A M Pereira, J A Romijn, R T Netea-Maier, A R Hermus, P M Zelissen, F H de Jong, A J van der Lely, W W de Herder, S M Webb, S W J Lamberts, L J Hofland, R A Feelders. Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.
Pituitary.
2013 Dec; 16(4):536-44. doi:
10.1007/s11102-012-0452-2. [PMID: 23225121] - Roberto Matorras, Maider Andrés, Rosario Mendoza, Begoña Prieto, Jose Ignacio Pijoan, Antonia Expósito. Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
European journal of obstetrics, gynecology, and reproductive biology.
2013 Oct; 170(2):439-43. doi:
10.1016/j.ejogrb.2013.07.010. [PMID: 23932181] - Aline B Moraes, Cintia Marques dos Santos Silva, Leonardo Vieira Neto, Mônica R Gadelha. Giant prolactinomas: the therapeutic approach.
Clinical endocrinology.
2013 Oct; 79(4):447-56. doi:
10.1111/cen.12242. [PMID: 23662975] - Hidetoshi Ikeda, Kazuo Watanabe, Teiji Tominaga, Takashi Yoshimoto. Transsphenoidal microsurgical results of female patients with prolactinomas.
Clinical neurology and neurosurgery.
2013 Sep; 115(9):1621-5. doi:
10.1016/j.clineuro.2013.02.016. [PMID: 23498159] - Lynnette K Nieman. Update in the medical therapy of Cushing's disease.
Current opinion in endocrinology, diabetes, and obesity.
2013 Aug; 20(4):330-4. doi:
10.1097/med.0b013e3283631809. [PMID: 23807605] - Juan J Díez, Pedro Iglesias. [Optimization of the medical treatment for acromegaly].
Medicina clinica.
2013 Apr; 140(8):360-5. doi:
10.1016/j.medcli.2012.07.024. [PMID: 23103101] - Kentaro Suda, Naoko Inoshita, Genzo Iguchi, Hidenori Fukuoka, Michiko Takahashi, Hitoshi Nishizawa, Masaaki Yamamoto, Shozo Yamada, Yutaka Takahashi. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Endocrine journal.
2013; 60(4):507-15. doi:
. [PMID: 23291436] - Renata S Auriemma, Luciana Granieri, Mariano Galdiero, Chiara Simeoli, Ylenia Perone, Pasquale Vitale, Claudia Pivonello, Mariarosaria Negri, Teresa Mannarino, Carla Giordano, Maurizio Gasperi, Annamaria Colao, Rosario Pivonello. Effect of cabergoline on metabolism in prolactinomas.
Neuroendocrinology.
2013; 98(4):299-310. doi:
10.1159/000357810. [PMID: 24355865] - Peter Cackett, Graeme Eunson, Louise Bath, Alan Mulvihill. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
Future oncology (London, England).
2012 Dec; 8(12):1621-6. doi:
10.2217/fon.12.149. [PMID: 23231524] - Jana Phillips, Honey E East, Sarah E French, Eugen Melcescu, Robert D Hamilton, William C Nicholas, Jonathan F Fratkin, Andrew D Parent, Gustavo Luzardo, Christian A Koch. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?.
Hormones (Athens, Greece).
2012 Oct; 11(4):477-82. doi:
10.14310/horm.2002.1380. [PMID: 23422771] - Seyyed Morteza Taghavi, Seyyede Sedighe Fatemi, Hale Rokni. Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure.
The Medical journal of Malaysia.
2012 Aug; 67(4):390-2. doi:
NULL. [PMID: 23082447] - Gennaro Bussone, Susanna Usai, Franca Moschiano. How to investigate and treat: headache and hyperprolactinemia.
Current pain and headache reports.
2012 Aug; 16(4):365-70. doi:
10.1007/s11916-012-0267-x. [PMID: 22639180] - P C Johnston, H C Courtney, S J Hunter, D R Mc Cance. Macroprolactinomas presenting as nasal polyps: a series of three cases.
Irish journal of medical science.
2012 Jun; 181(2):277-9. doi:
10.1007/s11845-009-0313-9. [PMID: 19288176] - D Nak, Y Nak, G Simsek. Comparison of the use of cabergoline and gonadotrophin to treat primary and secondary anoestrus in bitches.
Australian veterinary journal.
2012 May; 90(5):194-6. doi:
10.1111/j.1751-0813.2012.00913.x. [PMID: 22510079] - C E Higham, A B Atkinson, S Aylwin, M Bidlingmaier, W M Drake, A Lewis, N M Martin, V Moyes, J Newell-Price, P J Trainer. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
The Journal of clinical endocrinology and metabolism.
2012 Apr; 97(4):1187-93. doi:
10.1210/jc.2011-2603. [PMID: 22278424] - Ramón Coronas, Jesús Cobo, Olga Giménez-Palop, Emilio Ortega, Manel Márquez. Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics.
Current drug safety.
2012 Apr; 7(2):92-8. doi:
10.2174/157488612802715753. [PMID: 22873493] - C D Gibson, W Karmally, D J McMahon, S L Wardlaw, J Korner. Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.
Diabetes, obesity & metabolism.
2012 Apr; 14(4):335-40. doi:
10.1111/j.1463-1326.2011.01534.x. [PMID: 22074059] - R van der Pas, C de Bruin, F W G Leebeek, M P M de Maat, D C Rijken, A M Pereira, J A Romijn, R T Netea-Maier, A R Hermus, P M J Zelissen, F H de Jong, A J van der Lely, W W de Herder, S W J Lamberts, L J Hofland, R A Feelders. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.
The Journal of clinical endocrinology and metabolism.
2012 Apr; 97(4):1303-10. doi:
10.1210/jc.2011-2753. [PMID: 22278425] - Ensieh Shahrokh Tehraninejad, Maryam Hafezi, Arezoo Arabipoor, Elham Aziminekoo, Mohammad Chehrazi, Akram Bahmanabadi. Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial.
Journal of assisted reproduction and genetics.
2012 Mar; 29(3):259-64. doi:
10.1007/s10815-011-9708-4. [PMID: 22231013] - Chih-Chin Lu, Ching-Jung Hsieh. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients.
The Kaohsiung journal of medical sciences.
2012 Feb; 28(2):94-9. doi:
10.1016/j.kjms.2011.10.030. [PMID: 22313536] - Evdoxia Tsigkaropoulou, Melpomeni Peppa, Christina Zompola, Emmanouil Rizos, Ioanna Xelioti, Sofia Chatziioannou, Anastasia Filippopoulou, Lefteris Lykouras. Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis.
Gender medicine.
2012 Feb; 9(1):56-60. doi:
10.1016/j.genm.2012.01.001. [PMID: 22333523] - Kaan Gulleroglu, Asburce Olgac, Umut Bayrakci, Ozlem Erdogan, Sibel Tulgar Kinik, Esra Baskin. Hyperprolactinemia as a rare cause of hypertension in chronic renal failure.
Renal failure.
2012; 34(6):792-4. doi:
10.3109/0886022x.2012.672313. [PMID: 22462393]